REGN vs. HALO
REGN (Regeneron Pharmaceuticals, Inc.) and HALO (Halozyme Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 10 years, REGN returned 5.35%/yr vs 22.84%/yr for HALO. At a 0.35 correlation, their price movements are largely independent.
Performance
REGN vs. HALO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, REGN achieves a -20.48% return, which is significantly lower than HALO's 3.27% return. Over the past 10 years, REGN has underperformed HALO with an annualized return of 5.35%, while HALO has yielded a comparatively higher 22.84% annualized return.
REGN
- 1D
- 0.11%
- 1M
- -14.00%
- YTD
- -20.48%
- 6M
- -17.20%
- 1Y
- 16.30%
- 3Y*
- -7.00%
- 5Y*
- 3.27%
- 10Y*
- 5.35%
HALO
- 1D
- -1.74%
- 1M
- 0.42%
- YTD
- 3.27%
- 6M
- 11.72%
- 1Y
- 28.75%
- 3Y*
- 27.10%
- 5Y*
- 10.19%
- 10Y*
- 22.84%
REGN vs. HALO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
REGN Regeneron Pharmaceuticals, Inc. | -20.48% | 8.96% | -18.90% | 21.73% | 14.25% | 30.72% | 28.66% | 0.53% | -0.65% | 2.42% |
HALO Halozyme Therapeutics, Inc. | 3.27% | 40.77% | 29.36% | -35.04% | 41.51% | -5.85% | 140.89% | 21.19% | -27.79% | 105.06% |
Correlation
The correlation between REGN and HALO is 0.37, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.37 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.33 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.33 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.36 |
Correlation (All Time) Calculated using the full available price history since Mar 16, 2004 | 0.35 |
Fundamentals
REGN:
$65.93B
HALO:
$8.54B
REGN:
$41.05
HALO:
$2.87
REGN:
14.91
HALO:
24.26
REGN:
4.42
HALO:
5.61
REGN:
2.10
HALO:
38.88
REGN:
$14.92B
HALO:
$1.51B
REGN:
$12.61B
HALO:
$1.23B
REGN:
$5.74B
HALO:
$980.05M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
REGN vs. HALO — Risk / Return Rank
REGN
HALO
REGN vs. HALO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Regeneron Pharmaceuticals, Inc. (REGN) and Halozyme Therapeutics, Inc. (HALO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| REGN | HALO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.36 | ||
| Sortino ratioReturn per unit of downside risk | -0.41 | ||
| Omega ratioGain probability vs. loss probability | 1.12 | 1.17 | -0.05 |
| Calmar ratioReturn relative to maximum drawdown | 0.70 | 1.14 | -0.44 |
| Martin ratioReturn relative to average drawdown | 2.16 | 2.16 | 0.00 |
Loading charts...
Drawdowns
REGN vs. HALO - Drawdown Comparison
The maximum REGN drawdown since its inception was -91.81%, which is greater than HALO's maximum drawdown of -74.26%. Use the drawdown chart below to compare losses from any high point for REGN and HALO.
Loading charts...
Drawdown Indicators
| REGN | HALO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.81% | -74.26% | -17.55% |
Max Drawdown (1Y)Largest decline over 1 year | -25.85% | -24.13% | -1.72% |
Max Drawdown (3Y)Largest decline over 3 years | -59.69% | -33.92% | -25.77% |
Max Drawdown (5Y)Largest decline over 5 years | -59.69% | -49.06% | -10.63% |
Max Drawdown (10Y)Largest decline over 10 years | -59.69% | -49.06% | -10.63% |
Current DrawdownCurrent decline from peak | -48.64% | -14.44% | -34.20% |
Average DrawdownAverage peak-to-trough decline | -42.45% | -31.88% | -10.57% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 8.33% | 12.73% | -4.40% |
Volatility
REGN vs. HALO - Volatility Comparison
Regeneron Pharmaceuticals, Inc. (REGN) has a higher volatility of 12.77% compared to Halozyme Therapeutics, Inc. (HALO) at 8.94%. This indicates that REGN's price experiences larger fluctuations and is considered to be riskier than HALO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| REGN | HALO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.77% | 8.94% | +3.83% |
Volatility (6M)Calculated over the trailing 6-month period | 22.14% | 24.02% | -1.88% |
Volatility (1Y)Calculated over the trailing 1-year period | 32.77% | 30.20% | +2.57% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 30.79% | 39.42% | -8.63% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 32.17% | 42.88% | -10.71% |
Dividends
REGN vs. HALO - Dividend Comparison
REGN's dividend yield for the trailing twelve months is around 0.59%, while HALO has not paid dividends to shareholders.
| Position | TTM | 2025 |
|---|---|---|
HALO Halozyme Therapeutics, Inc. | 0.00% | 0.00% |
REGN Regeneron Pharmaceuticals, Inc. | 0.59% | 0.46% |
Financials
REGN vs. HALO - Financials Comparison
This section allows you to compare key financial metrics between Regeneron Pharmaceuticals, Inc. and Halozyme Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
REGN vs. HALO - Profitability Comparison
REGN - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a gross profit of 2.94B and revenue of 3.61B. Therefore, the gross margin over that period was 81.4%.
HALO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a gross profit of 297.47M and revenue of 376.71M. Therefore, the gross margin over that period was 79.0%.
REGN - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported an operating income of 642.90M and revenue of 3.61B, resulting in an operating margin of 17.8%.
HALO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported an operating income of 184.52M and revenue of 376.71M, resulting in an operating margin of 49.0%.
REGN - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Regeneron Pharmaceuticals, Inc. reported a net income of 727.20M and revenue of 3.61B, resulting in a net margin of 20.2%.
HALO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Halozyme Therapeutics, Inc. reported a net income of 150.05M and revenue of 376.71M, resulting in a net margin of 39.8%.
Frequently Asked Questions
REGN and HALO have a correlation of 0.37, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
REGN has higher volatility (12.77%) compared to HALO (8.94%). In terms of maximum drawdown, REGN dropped -91.81% vs HALO's -74.26%.
HALO currently has the higher Sharpe Ratio (0.91 vs 0.55), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for REGN and HALO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer